Sign up
Pharma Capital

MaxCyte appoints biotech pioneer as independent director

Richard Douglas was senior vice president of corporate development and corporate officer at Genzyme Corporation from 1989 until its sale to Sanofi in 2011
boardroom table
There will be a new face around the boardroom table

MaxCyte PLC (LON:MXCT) has appointed a new independent director who brings with him three decades’ of experience in the life sciences industry gleaned working with one of the pioneers of biotechnology.

He is Richard Douglas, who was senior vice president of corporate development and corporate officer at Genzyme Corporation from 1989 until its sale to Sanofi in 2011.

READ: MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

During this period he led numerous acquisitions, licences, financings, joint ventures and strategic alliances.

He currently serves as an advisor to RedSky Partners, a biotechnology-focused advisory firm.

Wealth of experience

MaxCyte chief executive Doug Doerfler said: “Richard's wealth of expertise in business and corporate development and his deep life sciences industry experience will bring invaluable perspective to the MaxCyte board.

"We are extremely pleased to have Richard as part of our organisation as we further our enablement of new medicines in the areas of gene editing and immuno-oncology, and move our first product candidate from our CARMA therapeutic platform into the clinic."

MaxCyte describes itself as a global cell-based medicines and technology company.

CARMA the bedrock of the business 

It has developed a technology called CARMA which is funded from its income and cash reserves.

This is being deployed to tackle cancer and it is hoped the platform will be spawn the next-generation immuno-oncology treatments that use the body’s own immune system to fight the disease.

What’s new and innovative, even for this very new and innovative strand of research, is that CARMA is being designed to grapple with solid tumours.

The breakthroughs in this field, such as CAR T-cell immuno-therapies, fight blood-borne illness, and yet 90% of cancers are solid tumours.

Why Invest In MaxCyte? Read More Here

Register here to be notified of future MXCT Company articles
View full MXCT profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.